Jonathan McNeill, Chief Business Officer at Dyne Therapeutics, Inc. (DYN), sold 39,591 shares at $19.03 ($670K) on 2024-01-03, disclosed to the SEC on 2024-01-04.
Scheduled sale ($670k) by Chief Business Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $13.10 | 11,900 | $156K | 23.3% |
| 2 | $18.34 | 7,691 | $141K | 21.0% |
| 3 | $18.34 | 7,691 | $141K | 21.0% |
| 4 | $19.03 | 10,300 | $196K | 29.2% |
| 5 | $18.04 | 2,009 | $36K | 5.4% |
| Total | $16.93 avg | 39,591 |
| $670K |
| 100% |
| Filing → |
| DYN | SELL | 2024-08-20 | $122K | — | Filing → |
| DYN | SELL | 2024-06-11 | $114K | — | Filing → |
| DYN | SELL | 2024-05-17 | $143K | — | Filing → |